SCHEMBL3403453

SCHEMBL3403453

Cc1nc(-c2ccc(Cl)cc2F)sc1C(=O)N1CCC(N2CCCCCC2)CC1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACKR3 P25106 1/20 0.49
HTR2C P28335 4/20 0.48
HRH3 Q9Y5N1 2/20 0.47
LMNA P02545 1/20 0.45
L3MBTL1 Q9Y468 7/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HSP90AA1 P07900 1/20 0.44
MAPT P10636 1/20 0.44
L3MBTL3 Q96JM7 6/20 0.43
MBTD1 Q05BQ5 3/20 0.42
THRA P10827 1/20 0.42
THRB P10828 1/20 0.42
CES2 O00748 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3402711 1.00 ACKR3 (0.49) ACKR3HTR2CHRH3LMNAL3MBTL1
SCHEMBL3405840 0.90 HTR2C (0.50) HTR2CLMNAL3MBTL1MEN1KMT2A
SCHEMBL3403297 0.90 L3MBTL1 (0.50) ACKR3HTR2CLMNAL3MBTL1MEN1
SCHEMBL3401249 0.90 HTR2C (0.50) HTR2CLMNAL3MBTL1MEN1KMT2A
SCHEMBL3400491 0.90 L3MBTL1 (0.50) ACKR3HTR2CLMNAL3MBTL1MEN1
SCHEMBL3405780 0.90 HTR2C (0.50) ACKR3HTR2CHRH3LMNAL3MBTL1
SCHEMBL3400371 0.90 HTR2C (0.50) ACKR3HTR2CHRH3LMNAL3MBTL1
SCHEMBL3402555 0.90 HTR2C (0.50) ACKR3HTR2CHRH3LMNAL3MBTL1
SCHEMBL3399767 0.90 HTR2C (0.50) ACKR3HTR2CHRH3LMNAL3MBTL1
SCHEMBL3402415 0.89 HTR2C (0.50) HTR2CHRH3LMNAL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues HRH3, HRH4, HRH2 ACKR3 245/4885HTR2C 416/4885HRH3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.